FGFR4 highly but variably expressed in DSRCT model: > [!info] Study [Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children’s Oncology Group (Scientific Reports | Nature 2020)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378211/) ><p align="justify">ChIP-seq for WT1 showed significant overlap with genes found to be highly expressed, including _IGF2_ and _FGFR4_, which were both highly expressed and targets of the EWS-WT1 fusion protein. In conclusion, we identified _IGF2_, _FGFR4, CD200_, and _CD276_ as potential therapeutic targets with clinical relevance for patients with DSRCT. Characterizing _FGFR4_ expression using a rank-ordered gene list revealed that DSRCT samples can be distinctly subcategorized into either FGFR4-high or FGFR4-low groups (Fig. [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378211/figure/Fig5/)D). Using the same mined gene expression dataset as above[14](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378211/#CR14), the expression levels of _FGFR4_ were noted to be statistically higher in DSRCT than in other fusion positive sarcomas with the exception of fusion-positive alveolar rhabdomyosarcoma</p> >Fig 5: EWS-WT1 regulates FGFR4 expression in DSRCT cells and exhibits variable expression in patient samples. (C) FGFR4 gene expression in patient samples (gray) and the JN-DSRCT-1 cell line (red). > **(D)** Characterization of FGFR4 expression in patient samples (gray) and the JN-DSRCT-1 cell line (red) using ranked gene list of all genes with TPM (log2) values > 2. > **(E)** Comparative analysis of FGFR4 expression across multiple fusion-positive pediatric sarcomas using gene expression array data. FGFR1 FGFR3 In DSRCT PDX model paper Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor [(2020)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212565/) ![[nihms-1649687-f0001.jpg]]